New Topics in Vasopressin Receptors and Approach to Novel Drugs:Vasopressin and Pain Perception
-
- Koshimizu Taka-aki
- Division of Molecular Pharmacology, Department of Pharmacology, Jichi Medical University, Japan
-
- Tsujimoto Gozoh
- Department of Genomic Drug Discovery Science, Kyoto University Graduate School of Pharmaceutical Sciences, Japan
Bibliographic Information
- Other Title
-
- Vasopressin and pain perception
Search this article
Abstract
Arginine vasopressin (AVP) activates three vasopressin receptors and it also has an agonistic activity on the oxytocin receptor. For an accurate description of the target receptor subtype(s) responsible for complex AVP and oxytocin actions, a careful evaluation of ligand specificity and receptor activities are required, particularly when these receptors are co-expressed in the central nervous system. Previous studies suggest that AVP plays a regulatory role in nociception through the direct activation of central vasopressin receptors and also through the receptors that reside in the peripheral tissues. Genetically altered rodent models, including the AVP-deficient mutant Brattleboro rat and gene knockout mice lacking an endogenous opioid peptide, advanced the understanding of the interactions between the pain perception process and AVP system. This report reviews previous findings in this important field and reconciles them with the findings of recent gene knockout/knockdown studies.<br>
Journal
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 109 (1), 33-37, 2009
The Japanese Pharmacological Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205178343680
-
- NII Article ID
- 10025733430
-
- NII Book ID
- AA11806667
-
- ISSN
- 13478648
- 13478613
-
- NDL BIB ID
- 9773052
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed